ReFacto AF (moroctocog alfa) Prescribing Information for Great Britain click here. ReFacto AF (moroctocog alfa) Prescribing Information for Northern Ireland click here.
Adverse event reporting information can be found at the bottom of the page.
ReFacto AF® (moroctocog alfa) is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). ReFacto AF® is appropriate for use in adults and children of all ages, including newborns. ReFacto AF® does not contain von Willebrand factor, and hence is not indicated in von Willebrand's disease.1
The dual-chamber FuseNGo device provides a fast and flexible patient experience, with a wide range of doses, and a convenient delivery method.1,2
ReFacto AF FuseNGo is available in a range of colour-coded doses (250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU)
A cross-sectional survey was conducted in Austria, Germany, Italy, Spain and the United Kingdom among adults (aged 18–65 years) with haemophilia A who used FVIII product for either prophylaxis or on-demand therapy at least once a month.2
The survey aimed to identify factors associated with adult patient preferences for different FVIII reconstitution systems and to test ease of use and patient preference for a new dual-chamber syringe.2
ReFacto AF® FuseNGo is ready in less than one minute (median time; IQR 27 seconds) vs. approximately 4 minutes for other factor VIII reconstitution systems (IQR 285 seconds).2
Over half (57%) of adult patients preferred ReFacto AF® FuseNGo to their current reconstitution system (n/N = 56/98).2
Patients indicated that they were significantly more likely (p <0.001 vs. FuseNGo) to use ReFacto AF® FuseNGo prophylactically as well as more often compared to their current reconstitution system.2
No two days are the same. No two patients are the same. ReFacto AF® offers frequent, flexible dosing so your patients are covered for everyday life.1,3,4
ReFacto AF® (and ReFacto®) have reliably supported you and your patients for over 20 years.1
The use of the ReFacto AF® Laboratory Standard allows for consistent results regardless of assay type.
Contact a member of the Pfizer haemophilia team.
** This is an optional area where footnotes can live.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021